Paper Details

  1. Home
  2. Paper Details

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

Author: , AmadoriSergio, BelhabriAmine, BourhisJean-Henri, De RosaGennaro, DelarueRichard, FaziPaola, FioritoniGiuseppe, GalloEugenio, GiustolisiRosario, HagemeijerAnne, JehnUlrich, LabarBoris, LeoneGiuseppe, LisoVincenzo, MandelliFranco, MirtoSalvatore, SuciuStefan, WillemzeRoel, ZittounRobert, de WitteTheo

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

In a study of 822 people under 46 who achieved remission from acute myeloid leukemia (AML), those who had a sibling who was a suitable bone marrow donor (allogeneic transplant) had a higher 4-year disease-free survival rate (52.2%) compared to those who did not have a suitable donor (42.2%). The difference was greater in people under 35 and those with poor risk factors. Overall, early allogeneic transplantation was more effective than autologous transplantation.
Paper Details　
Original Abstract of the Article :
In the European Organization for Research and Treatment of Cancer Leukemia Group and Gruppo Italiano Malattie Ematologiche dell' Adulto (EORTC-LG/GIMEMA) acute myeloid leukemia (AML)-10 trial, patients in first complete remission (CR1) received a single intensive consolidation (IC) course. Subsequen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12714526

データ提供：米国国立医学図書館（NLM）

Stem Cell Transplant for Acute Myeloid Leukemia: A Camel's Journey Through Treatment Options

Acute myeloid leukemia (AML) is a serious blood cancer where bone marrow produces abnormal white blood cells. It's like a sandstorm, wreaking havoc on the body's defenses. This study focuses on patients younger than 46 years old who have achieved complete remission after an initial treatment. The researchers compared two approaches – allogeneic stem cell transplantation (allo-SCT), which uses cells from a donor, and autologous stem cell transplantation (auto-SCT), which uses the patient's own cells. The study aims to determine which approach is more effective in preventing the return of the disease. The researchers found that allogeneic stem cell transplantation, especially in younger patients, showed a significant advantage in disease-free survival, emphasizing the importance of donor availability.

Navigating the Sandstorms of Leukemia: A Camel's Perspective

This study provides valuable insights into the treatment of AML. The researchers discovered that allogeneic stem cell transplantation offers a significant advantage in preventing relapse, particularly in younger patients. It's like using a camel caravan to overcome the sandstorm, providing a more effective defense against the return of the disease.

Stem Cell Transplantation: A Camel's Guide to Staying Healthy

This research underscores the importance of early intervention and utilizing all available resources for AML treatment. If a donor is available, allogeneic stem cell transplantation can be a life-saving option, particularly for younger patients. It's a reminder that we should always be prepared to face the sandstorms of life with the right tools and knowledge.

Dr. Camel's Conclusion

AML is a challenging battle, but this research offers hope. Allogeneic stem cell transplantation, especially for younger patients, shows promising results in combating the disease. It's a reminder that we can navigate even the most difficult sandstorms with the right tools and strategies.

Date :
  1. Date Completed 2003-09-11
  2. Date Revised 2021-02-06
Further Info :

Pubmed ID

12714526

DOI: Digital Object Identifier

S0006-4971(20)44288-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.